C3.ai Inc vs Cytokinetics Inc — how do they compare? C3.ai Inc trades at $10.6 (market cap $1.59B), while Cytokinetics Inc trades at $77.39 (market cap $10.78B). The key difference: Cytokinetics Inc is far larger — about 6.8× C3.ai Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, C3.ai Inc nearer its low. Which is the better fit depends on your goals.
| AI | CYTK | |
|---|---|---|
Market Cap | $1.59B | $10.78B |
Sector | Technology | Technology |
52-Week High | $19.66 | $87.26 |
52-Week Low | $7.76 | $34.31 |
Enterprise Value | $1.02B | $10.88B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
Trailing returns across standard periods
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Suite, is a comprehensive application development and runtime environment that is designed to allow customers to rapidly design, develop, and deploy Enterprise AI applications of any type
Read more on AI →Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →